Drug Trial Radar · NCT06661720
Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surgery to Remove All Known Sites of Kidney Cancer
Last checked: Nov 19, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
1,040
Planned (sponsor's estimate)
Start
Mar 14, 2025
Primary completion
Nov 2037
Study completion Nov 2037
Sponsor
- Lead sponsor
- Alliance for Clinical Trials in OncologyAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Oct 28, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This phase III trial compares the effect of adding tivozanib to standard therapy pembrolizumab versus pembrolizumab alone for the treatment of patients with high-risk renal cell carcinoma (RCC). Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Tivozanib is in a class of medications called kinase inhibitors. It works by blocking the action of the abnormal protein that signals tumor cells to multiply. This helps stop the spread of tumor cells. Giving pembrolizumab and tivozanib together may work better than pembrolizumab alone in treating patients with RCC.
Conditions
- Clear Cell Renal Cell Carcinoma
- Renal Cell Carcinoma (RCC)
- Stage II Renal Pelvis Cancer AJCC v8
- Stage III Renal Pelvis Cancer AJCC v8
Interventions
PembrolizumabBiological
Given intravenously
TivozanibDrug
Given orally
Biospecimen CollectionProcedure
Undergo blood sample collection
MRIProcedure
Undergo MRI
Computed TomographyProcedure
Undergo CT scan
BiopsyProcedure
Undergo biopsy
Questionnaire AdministrationOther
Ancillary studies
Primary outcomes
What the sponsor says the trial is designed to measure.
- Disease-free survival (DFS)Time frame: From time of randomization until disease recurrence or death, assessed up to 10 years
Locations
429 sites in 1 country. Site status is shown where the registry gives one.
Cancer Center at Saint Joseph's
Phoenix, Arizona · Active not recruiting
Banner University Medical Center - Tucson
Tucson, Arizona · Recruiting
University of Arizona Cancer Center-North Campus
Tucson, Arizona · Recruiting
NEA Baptist Memorial Hospital and Fowler Family Cancer Center - Jonesboro
Jonesboro, Arkansas · Recruiting
University of Arkansas for Medical Sciences
Little Rock, Arkansas · Recruiting
Sutter Auburn Faith Hospital
Auburn, California · Recruiting
Tower Cancer Research Foundation
Beverly Hills, California · Recruiting
City of Hope Comprehensive Cancer Center
Duarte, California · Recruiting
UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care
Irvine, California · Recruiting
City of Hope at Irvine Lennar
Irvine, California · Recruiting
UC San Diego Moores Cancer Center
La Jolla, California · Recruiting
City of Hope Antelope Valley
Lancaster, California · Recruiting
Los Angeles General Medical Center
Los Angeles, California · Recruiting
USC / Norris Comprehensive Cancer Center
Los Angeles, California · Recruiting
Cedars-Sinai Medical Center
Los Angeles, California · Recruiting
UCLA / Jonsson Comprehensive Cancer Center
Los Angeles, California · Recruiting
Memorial Medical Center
Modesto, California · Recruiting
USC Norris Oncology/Hematology-Newport Beach
Newport Beach, California · Recruiting
UC Irvine Health/Chao Family Comprehensive Cancer Center
Orange, California · Recruiting
Palo Alto Medical Foundation Health Care
Palo Alto, California · Recruiting
Sutter Roseville Medical Center
Roseville, California · Recruiting
Sutter Medical Center Sacramento
Sacramento, California · Recruiting
University of California Davis Comprehensive Cancer Center
Sacramento, California · Recruiting
UC San Diego Medical Center - Hillcrest
San Diego, California · Recruiting
California Pacific Medical Center-Pacific Campus
San Francisco, California · Recruiting
Mills Health Center
San Mateo, California · Recruiting
Palo Alto Medical Foundation-Santa Cruz
Santa Cruz, California · Recruiting
Palo Alto Medical Foundation-Sunnyvale
Sunnyvale, California · Recruiting
City of Hope South Bay
Torrance, California · Recruiting
Torrance Memorial Physician Network - Cancer Care
Torrance, California · Recruiting
City of Hope Upland
Upland, California · Recruiting
Sutter Solano Medical Center/Cancer Center
Vallejo, California · Recruiting
UCHealth University of Colorado Hospital
Aurora, Colorado · Recruiting
UCHealth Memorial Hospital Central
Colorado Springs, Colorado · Recruiting
Memorial Hospital North
Colorado Springs, Colorado · Recruiting
UCHealth - Cherry Creek
Denver, Colorado · Recruiting
Poudre Valley Hospital
Fort Collins, Colorado · Recruiting
Cancer Care and Hematology-Fort Collins
Fort Collins, Colorado · Recruiting
UCHealth Greeley Hospital
Greeley, Colorado · Recruiting
UCHealth Highlands Ranch Hospital
Highlands Ranch, Colorado · Recruiting
Showing 40 of 429 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.